Could a tiny dose of magic mushrooms help teens stop Self-Harming?
NCT ID NCT06798636
First seen Jan 06, 2026
Summary
This early-phase study at Imperial College London is testing whether a low, non-hallucinogenic dose of psilocybin (the active ingredient in magic mushrooms) can make a mental imagery therapy more effective for young people aged 16-25 who self-harm. The therapy, called Imagery Re-Scripting, helps replace distressing mental images that drive self-harm with healthier ones. The study aims to see if psilocybin helps participants tolerate difficult emotions and become more open to change during therapy. Only 30 participants will be enrolled, and the focus is on understanding how the combination works, not yet on proving it as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SELF HARM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Imperial College London
RECRUITINGLondon, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Psilocybin (5 mg oral dose)
What this could lead to
If successful, this could point toward a new treatment approach for self-harm in young people by combining low-dose psychedelics with cognitive therapy.
What could go wrong
This is a very early, small study (30 participants) focused on understanding mechanisms, not proving effectiveness. The low dose may not produce meaningful changes, and results may not generalize.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.